Cargando…
Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies
BACKGROUND AND AIMS: Many patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interpla...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Diabetes India. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286828/ https://www.ncbi.nlm.nih.gov/pubmed/32540733 http://dx.doi.org/10.1016/j.dsx.2020.06.016 |
_version_ | 1783544936810938368 |
---|---|
author | Costa, Fernanda Farias Rosário, Wilian Reis Ribeiro Farias, Ana Cláudia de Souza, Ramon Guimarães Duarte Gondim, Roberta Sabrine Barroso, Wermerson Assunção |
author_facet | Costa, Fernanda Farias Rosário, Wilian Reis Ribeiro Farias, Ana Cláudia de Souza, Ramon Guimarães Duarte Gondim, Roberta Sabrine Barroso, Wermerson Assunção |
author_sort | Costa, Fernanda Farias |
collection | PubMed |
description | BACKGROUND AND AIMS: Many patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interplay between MS, COVID-19 and proposed therapies is required for optimum management of these patients. METHODS: We systematically searched the PubMed and Google Scholar databases until June 1st, 2020 and accessed the full text on COVID-19 and MS to prepare a narrative review on this topic. RESULTS: Patients with metabolic disorders like obesity, diabetes, cardiovascular and liver disease may face a higher risk of infection of COVID-19, greatly affecting the development and prognosis of the disease, being associated with significantly worse outcome in these patients. The proposed drugs that are in clinical trial for COVID-19 treatment must be carefully considered for clinical use, especially in patients with MS. CONCLUSION: MS is a risk factor influencing the progression and prognosis of COVID-2019. The drugs currently evaluated for the infection treatment are promising but need further studies to prove their efficacy and safety, due to the adverse effects may be exacerbated by combination therapy or due to viral infection. The development of a vaccine for immunization is still the best long-term solution. |
format | Online Article Text |
id | pubmed-7286828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Diabetes India. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72868282020-06-11 Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies Costa, Fernanda Farias Rosário, Wilian Reis Ribeiro Farias, Ana Cláudia de Souza, Ramon Guimarães Duarte Gondim, Roberta Sabrine Barroso, Wermerson Assunção Diabetes Metab Syndr Article BACKGROUND AND AIMS: Many patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interplay between MS, COVID-19 and proposed therapies is required for optimum management of these patients. METHODS: We systematically searched the PubMed and Google Scholar databases until June 1st, 2020 and accessed the full text on COVID-19 and MS to prepare a narrative review on this topic. RESULTS: Patients with metabolic disorders like obesity, diabetes, cardiovascular and liver disease may face a higher risk of infection of COVID-19, greatly affecting the development and prognosis of the disease, being associated with significantly worse outcome in these patients. The proposed drugs that are in clinical trial for COVID-19 treatment must be carefully considered for clinical use, especially in patients with MS. CONCLUSION: MS is a risk factor influencing the progression and prognosis of COVID-2019. The drugs currently evaluated for the infection treatment are promising but need further studies to prove their efficacy and safety, due to the adverse effects may be exacerbated by combination therapy or due to viral infection. The development of a vaccine for immunization is still the best long-term solution. Diabetes India. Published by Elsevier Ltd. 2020 2020-06-11 /pmc/articles/PMC7286828/ /pubmed/32540733 http://dx.doi.org/10.1016/j.dsx.2020.06.016 Text en © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Costa, Fernanda Farias Rosário, Wilian Reis Ribeiro Farias, Ana Cláudia de Souza, Ramon Guimarães Duarte Gondim, Roberta Sabrine Barroso, Wermerson Assunção Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies |
title | Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies |
title_full | Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies |
title_fullStr | Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies |
title_full_unstemmed | Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies |
title_short | Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies |
title_sort | metabolic syndrome and covid-19: an update on the associated comorbidities and proposed therapies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286828/ https://www.ncbi.nlm.nih.gov/pubmed/32540733 http://dx.doi.org/10.1016/j.dsx.2020.06.016 |
work_keys_str_mv | AT costafernandafarias metabolicsyndromeandcovid19anupdateontheassociatedcomorbiditiesandproposedtherapies AT rosariowilianreis metabolicsyndromeandcovid19anupdateontheassociatedcomorbiditiesandproposedtherapies AT ribeirofariasanaclaudia metabolicsyndromeandcovid19anupdateontheassociatedcomorbiditiesandproposedtherapies AT desouzaramonguimaraes metabolicsyndromeandcovid19anupdateontheassociatedcomorbiditiesandproposedtherapies AT duartegondimrobertasabrine metabolicsyndromeandcovid19anupdateontheassociatedcomorbiditiesandproposedtherapies AT barrosowermersonassuncao metabolicsyndromeandcovid19anupdateontheassociatedcomorbiditiesandproposedtherapies |